Muhammad Wasif Saif
#118,873
Most Influential Person Now
Researcher
Muhammad Wasif Saif's AcademicInfluence.com Rankings
Muhammad Wasif Saifcomputer-science Degrees
Computer Science
#4723
World Rank
#4986
Historical Rank
Computational Linguistics
#514
World Rank
#522
Historical Rank
Machine Learning
#1024
World Rank
#1039
Historical Rank
Artificial Intelligence
#1247
World Rank
#1270
Historical Rank
Download Badge
Computer Science
Why Is Muhammad Wasif Saif Influential?
(Suggest an Edit or Addition)Muhammad Wasif Saif's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study (2020) (1264)
- Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. (2008) (575)
- Diabetes and pancreatic cancer. (2013) (218)
- Gastrointestinal Perforation Due to Bevacizumab in Colorectal Cancer (2007) (204)
- Hypersensitivity Reactions Associated with Platinum Antineoplastic Agents: A Systematic Review (2010) (169)
- The role of mTOR in the management of solid tumors: an overview. (2009) (169)
- Autoimmune Phenomena in Patients with Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia (2002) (153)
- Increased Prevalence of Dihydropyrimidine Dehydrogenase Deficiency in African-Americans Compared with Caucasians (2006) (147)
- Fluoropyrimidine-associated cardiotoxicity: revisited (2009) (145)
- AIDS and thrombosis: retrospective study of 131 HIV-infected patients. (2001) (138)
- HIV and thrombosis: a review. (2001) (137)
- Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials. (2014) (135)
- Gastric cancer in the elderly: an overview. (2010) (134)
- Panitumumab the first fully human monoclonal antibody: from the bench to the clinic (2007) (132)
- Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer. (2010) (129)
- Disparities in colorectal cancer in African-Americans vs Whites: before and after diagnosis. (2009) (120)
- Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study. (2020) (113)
- Primary pancreatic lymphomas. (2006) (112)
- Role and Cost Effectiveness of PET/CT in Management of Patients with Cancer (2010) (110)
- Incidence and management of bevacizumab-related toxicities in colorectal cancer (2006) (106)
- Pancreatic neoplasm in 2011: an update. (2011) (100)
- Pancreatic cancer: from molecular pathogenesis to targeted therapy (2008) (98)
- Chemotherapy for intraperitoneal use: a review of hyperthermic intraperitoneal chemotherapy and early post-operative intraperitoneal chemotherapy. (2016) (98)
- The Biological Role of PI3K Pathway in Lung Cancer (2012) (93)
- Role of pregabalin in treatment of oxaliplatin-induced sensory neuropathy. (2010) (92)
- Infusion-related and hypersensitivity reactions of monoclonal antibodies used to treat colorectal cancer--identification, prevention, and management. (2007) (91)
- Cancers of the Appendix: Review of the Literatures (2011) (90)
- Emergency use of uridine triacetate for the prevention and treatment of life‐threatening 5‐fluorouracil and capecitabine toxicity (2016) (84)
- Adjuvant therapy of pancreatic cancer. (2012) (80)
- The safety and efficacy of Onivyde (irinotecan liposome injection) for the treatment of metastatic pancreatic cancer following gemcitabine-based therapy (2016) (80)
- Capecitabine: an overview of the side effects and their management (2008) (79)
- Serum Alkaline Phosphatase Level as a Prognostic Tool in Colorectal Cancer: A Study of 105 patients. (2005) (79)
- Phase II Clinical Trial of Paclitaxel Loaded Polymeric Micelle in Patients with Advanced Pancreatic Cancer (2009) (77)
- Biology of Colorectal Cancer (2010) (74)
- Fluoropyrimidine-associated cardiotoxicity: revisited. (2009) (74)
- Identification of chemicals and their metabolites from PHY906, a Chinese medicine formulation, in the plasma of a patient treated with irinotecan and PHY906 using liquid chromatography/tandem mass spectrometry (LC/MS/MS). (2010) (70)
- Impact of age and medical comorbidity on adjuvant treatment outcomes for stage III colon cancer: a pooled analysis of individual patient data from four randomized, controlled trials. (2015) (70)
- Antitumor Efficacy of Capecitabine and Celecoxib in Irradiated and Lead-Shielded, Contralateral Human BxPC-3 Pancreatic Cancer Xenografts: Clinical Implications of Abscopal Effects (2005) (70)
- Phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: expression analysis of genes related to outcome. (2005) (69)
- Hepatocellular carcinoma: current management. (2010) (68)
- Incidence and implications of chemotherapy related hand-foot syndrome (2016) (67)
- Supportive and palliative care of pancreatic cancer. (2007) (67)
- Phase I/II study of PHY906/capecitabine in advanced hepatocellular carcinoma. (2009) (67)
- Controversies in the adjuvant treatment of pancreatic adenocarcinoma. (2007) (66)
- Review. Colon cancer vaccines: an update. (2010) (65)
- First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second-line therapy in patients with advanced pancreatic cancer (2014) (64)
- Aurora kinase inhibitors as anti-cancer therapy (2010) (64)
- Management of regorafenib-related toxicities: a review (2015) (62)
- S-1: a promising new oral fluoropyrimidine derivative. (2009) (61)
- DPYD*2A mutation: the most common mutation associated with DPD deficiency (2007) (60)
- Gastric cancer and trastuzumab: first biologic therapy in gastric cancer (2013) (60)
- Overcoming the stromal barrier: technologies to optimize drug delivery in pancreatic cancer (2012) (57)
- Desmoplasia in Pancreatic Cancer. Can We Fight It? (2012) (57)
- A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy. (2013) (57)
- Anti-angiogenesis therapy in pancreatic carcinoma. (2006) (57)
- Colorectal cancer in review: the role of the EGFR pathway (2010) (56)
- Advancements in the management of pancreatic cancer. (2009) (56)
- Hemolytic-uremic syndrome associated with gemcitabine: a case report and review of literature. (2005) (55)
- Skeletal Metastases in Pancreatic Cancer: A Retrospective Study and Review of the Literature (2009) (55)
- Phase 1 study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856/IMC-3C5 in patients with advanced and refractory solid tumors and advanced colorectal cancer (2016) (53)
- Why HALO 301 Failed and Implications for Treatment of Pancreatic Cancer (2019) (52)
- Capecitabine and hand–foot syndrome (2011) (51)
- Advancements in the management of pancreatic cancer: 2013. (2013) (51)
- Randomized Double-Blind Phase II Trial Comparing Gemcitabine Plus LY293111 Versus Gemcitabine Plus Placebo in Advanced Adenocarcinoma of the Pancreas (2009) (50)
- Hypersensitivity reactions to antineoplastic agents: an overview (2009) (50)
- Pancreatic cancer: highlights from the 42nd annual meeting of the American Society of Clinical Oncology, 2006. (2006) (49)
- Management of ascites due to gastrointestinal malignancy. (2009) (49)
- Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors (2014) (49)
- Dihydropyrimidine dehydrogenase gene (DPYD) polymorphism among Caucasian and non-Caucasian patients with 5-FU- and capecitabine-related toxicity using full sequencing of DPYD. (2013) (48)
- Erlotinib-induced skin rash in patients with non-small-cell lung cancer: pathogenesis, clinical significance, and management. (2009) (48)
- Colon Cancer Vaccines : An Update (2010) (48)
- Phase 1 Study of Weekly Polyethylene Glycol-Camptothecin in Patients with Advanced Solid Tumors and Lymphomas (2005) (48)
- Skin rash secondary to bevacizumab in a patient with advanced colorectal cancer and relation to response. (2006) (47)
- HIV-associated autoimmune hemolytic anemia: an update. (2001) (47)
- Phase II Study of Capecitabine With Concomitant Radiotherapy for Patients With Locally Advanced Pancreatic Cancer: Up-Regulation of Thymidine Phosphorylase (2007) (47)
- Assessing risk and mortality of venous thromboembolism in pancreatic cancer patients. (2010) (46)
- Safety and efficacy of panitumumab therapy after progression with cetuximab: experience at two institutions. (2010) (46)
- A Phase 1, Dose-Escalation, Pharmacokinetic and Pharmacodynamic Study of BIIB021 Administered Orally in Patients with Advanced Solid Tumors (2013) (45)
- Prolonged survival in a patient with BRCA2 associated metastatic pancreatic cancer after exposure to camptothecin: a case report and review of literature. (2009) (45)
- S-1: a promising new oral fluoropyrimidine derivative (2009) (45)
- Is there an optimal neoadjuvant therapy for locally advanced pancreatic cancer? (2007) (44)
- Peripheral neuropathy associated with capecitabine (2004) (44)
- Immunotherapy for pancreatic cancer (2016) (44)
- Successful re-challenge with panitumumab in patients who developed hypersensitivity reactions to cetuximab: report of three cases and review of literature (2009) (44)
- BIIB021, an oral, synthetic non-ansamycin Hsp90 inhibitor: Phase I experience (2008) (43)
- Hypersensitivity reactions to oxaliplatin and other antineoplastic agents (2008) (43)
- Anti-VEGF agents in metastatic colorectal cancer (mCRC): are they all alike? (2013) (43)
- First-line treatment for advanced pancreatic cancer. (2013) (42)
- Epidermal growth factor receptor inhibition strategies in pancreatic cancer: past, present and the future. (2007) (42)
- IGF system in cancer: from bench to clinic (2011) (41)
- Management of hypomagnesemia in cancer patients receiving chemotherapy. (2008) (40)
- Capecitabine-related cardiotoxicity: recognition and management. (2008) (40)
- Methods and rationale for the early detection of pancreatic cancer. Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010. (2010) (40)
- DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY (DPD) IN GI MALIGNANCIES: EXPERIENCE OF 4-YEARS. (2006) (40)
- First-line treatment for advanced pancreatic cancer. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011. (2011) (39)
- An adverse interaction between warfarin and fluoropyrimidines revisited. (2005) (39)
- Genetic alterations in pancreatic cancer. (2007) (39)
- Treatment of locally advanced pancreatic cancer: the role of radiation therapy. (2012) (38)
- Incidence and management of cutaneous toxicities associated with cetuximab (2007) (38)
- Long-term survival in a patient with acinar cell carcinoma of pancreas. A case report and review of literature. (2007) (38)
- Correlation between rash and a positive drug response associated with bevacizumab in a patient with advanced colorectal cancer. (2008) (37)
- Hypersensitivity Reactions to Docetaxel: Retrospective Evaluation and Development of a Desensitization Protocol (2010) (37)
- 18F-FDG positron emission tomography CT (FDG PET-CT) in the management of pancreatic cancer: initial experience in 12 patients. (2008) (37)
- Hypersensitivity reactions associated with oxaliplatin (2006) (37)
- Necrosis and apoptotic index as prognostic factors in non-small cell lung carcinoma: a review (2014) (37)
- Capecitabine as a Radiosensitizer in Adjuvant Chemoradiotherapy for Pancreatic Cancer: A Retrospective Study. (2015) (37)
- Nutritional status of patients with locally advanced pancreatic cancer: a pilot study (2011) (36)
- Clinical outcomes in pancreatic adenocarcinoma associated with BRCA-2 mutation (2015) (35)
- Metformin and pancreatic cancer: Is there a role? (2016) (35)
- Bleeding diathesis in multiple myeloma. (2001) (35)
- Is capecitabine safe in patients with gastrointestinal cancer and dihydropyrimidine dehydrogenase deficiency? (2006) (35)
- The molecular targets for the diagnosis and treatment of pancreatic cancer. (2010) (35)
- Management of ascites due to gastrointestinal malignancy (2009) (34)
- A DPYD variant (Y186C) specific to individuals of African descent in a patient with life-threatening 5-FU toxic effects: potential for an individualized medicine approach. (2014) (33)
- Multimodal treatment strategies for elderly patients with head and neck cancer. (2014) (33)
- Cryptococcal Peritonitis Complicating Hepatic Failure: Case Report and Review of the Literature. (2006) (33)
- Profile of capecitabine/temozolomide combination in the treatment of well-differentiated neuroendocrine tumors (2016) (32)
- Toxicity and efficacy of 5-fluorouracil and capecitabine in a patient with TYMS gene polymorphism: A challenge or a dilemma? (2009) (32)
- Pharmacogenetics and biomarkers in colorectal cancer (2009) (32)
- U.S. Food and Drug Administration approves paclitaxel protein-bound particles (Abraxane®) in combination with gemcitabine as first-line treatment of patients with metastatic pancreatic cancer. (2013) (32)
- Harnessing gemcitabine metabolism: a step towards personalized medicine for pancreatic cancer (2012) (31)
- Epidemiology of active tuberculosis in lung cancer patients: a systematic review (2014) (31)
- Depression and pancreatic cancer: a poorly understood link. (2009) (30)
- Enterococcus Faecalis Infective Endocarditis and Colorectal Carcinoma: Case of New Association Gaining Ground (2018) (30)
- Hedgehog Pathway Expression in Heterogeneous Pancreatic Adenocarcinoma: Implications for the Molecular Analysis of Clinically Available Biopsies (2007) (30)
- Diabetes Type 2 and Pancreatic Cancer: A History Unfolding. (2016) (30)
- Biomarkers for early detection and screening in pancreatic cancer. Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009. (2009) (30)
- A retrospective study of coagulation abnormalities in patients receiving concomitant capecitabine and warfarin. (2006) (30)
- Benefit of uridine triacetate (Vistogard) in rescuing severe 5-fluorouracil toxicity in patients with dihydropyrimidine dehydrogenase (DPYD) deficiency (2016) (30)
- Nutrition habits, physical activity, and lung cancer: an authoritative review. (2013) (29)
- First-Line Treatment for Advanced Pancreatic Cancer Highlights from the “ 2013 ASCO Gastrointestinal Cancers Symposium ” (2013) (29)
- Open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of intravenously administered CNF1010 (17-(allylamino)-17-demethoxygeldanamycin [17-AAG]) in patients with solid tumors (2013) (29)
- New developments in the treatment of pancreatic cancer. Highlights from the "44th ASCO Annual Meeting". Chicago, IL, USA. May 30 - June 3, 2008. (2008) (29)
- Hypersensitivity reactions to oxaliplatin: a retrospective study and the development of a desensitization protocol. (2009) (28)
- Pharmacogenomics and pancreatic cancer treatment. Optimizing current therapy and individualizing future therapy. (2008) (28)
- Mixed Acinar-Neuroendocrine Carcinoma of the Pancreas with Neuroendocrine Predominance (2013) (28)
- Edotecarin: a novel topoisomerase I inhibitor. (2005) (28)
- Docetaxel second-line therapy in patients with advanced pancreatic cancer: a retrospective study. (2010) (27)
- Locally advanced unresectable pancreatic cancer. (2014) (27)
- Erlotinib-induced skin rash. Pathogenesis, clinical significance and management in pancreatic cancer patients. (2008) (27)
- Incidence and management of colorectal cancer in liver transplant recipients. (2008) (27)
- Successful amelioration of oxaliplatin-induced hyperexcitability syndrome with the antiepileptic pregabalin in a patient with pancreatic cancer (2008) (27)
- Oxaliplatin-induced immune thrombocytopenia: another cumulative dose-dependent side effect? (2009) (26)
- Targeted therapy for oesophageal cancer: an overview (2008) (26)
- The need for third-line treatment in non-small cell lung cancer: an overview of new options. (2011) (26)
- Emerging therapies and latest development in the treatment of unresectable pancreatic neuroendocrine tumors: an update for clinicians (2013) (26)
- Screening for early pancreatic ductal adenocarcinoma: an urgent call! (2009) (26)
- Gemcitabine-induced pulmonary toxicity. (2012) (25)
- Dihydropyrimidine dehydrogenase deficiency in an Indian population (2006) (25)
- Pancreatic enzyme supplementation in pancreatic cancer. (2008) (25)
- Gemcitabine-induced pulmonary toxicity during adjuvant therapy in a patient with pancreatic cancer. (2008) (25)
- Reactivation of chronic hepatitis B infection following intensive chemotherapy and successful treatment with lamivudine: a case report and review of the literature. (2001) (24)
- Update on the role of nanoliposomal irinotecan in the treatment of metastatic pancreatic cancer (2017) (24)
- Stereotactic body radiation therapy (SBRT) in pancreatic cancer: is it ready for prime time? (2008) (24)
- Chemotherapy: Metastatic pancreatic cancer—is FOLFIRINOX the new standard? (2011) (24)
- Thrombotic microangiopathy associated with gemcitabine: rare but real (2009) (24)
- Bolus 5-fluorouracil as an alternative in patients with cardiotoxicity associated with infusion 5-fluorouracil and capecitabine: a case series. (2013) (24)
- Pancreatic cancer: is this bleak landscape finally changing? Highlights from the '43rd ASCO Annual Meeting'. Chicago, IL, USA. June 1-5, 2007. (2007) (23)
- DIC secondary to acute pancreatitis. (2005) (23)
- Heat shock protein inhibitors and vaccines as new agents in cancer treatment. (2009) (23)
- Neuroendocrine tumors of the pancreas: what's new. Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010. (2010) (23)
- Tesetaxel, a new oral taxane, in combination with capecitabine: a phase I, dose-escalation study in patients with advanced solid tumors (2011) (23)
- Capecitabine versus continuous-infusion 5-fluorouracil for colorectal cancer: a retrospective efficacy and safety comparison. (2005) (22)
- Radiation recall phenomenon secondary to bevacizumab in a patient with pancreatic cancer. (2008) (22)
- Erlotinib-induced acute hepatitis in a patient with pancreatic cancer. (2008) (22)
- The Role of EGFR Inhibitors in the Treatment of Metastatic Anal Canal Carcinoma: A Case Series (2011) (22)
- Optimal second line treatment options for gemcitabine refractory advanced pancreatic cancer patients. Can we establish standard of care with available data? (2008) (22)
- Is there a standard of care for the management of advanced pancreatic cancer?. Highlights from the Gastrointestinal Cancers Symposium. Orlando, FL, USA. January 25-27, 2008. (2008) (22)
- Fever as the only manifestation of hypersensitivity reactions associated with oxaliplatin in a patient with colorectal cancer Oxaliplatin-induced hypersensitivity reaction. (2007) (22)
- Hand-foot syndrome variant in a dihydropyrimidine dehydrogenase-deficient patient treated with capecitabine. (2006) (21)
- Radiation recall phenomenon secondary to capecitabine: possible role of thymidine phosphorylase (2006) (21)
- Update on phase I studies in advanced pancreatic adenocarcinoma. Hunting in darkness? (2013) (21)
- Gemcitabine-related radiation recall in a patient with pancreatic cancer. (2006) (21)
- Multiple Myeloma and Hairy Cell Leukemia: A Rare Association or Coincidence? (2001) (21)
- Quality of life in patients with pancreatic cancer. (2012) (21)
- Secondary hepatic resection as a therapeutic goal in advanced colorectal cancer. (2009) (21)
- Any progress in the management of advanced pancreatic cancer? Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009. (2009) (21)
- PARP-inhibitors in BRCA-associated pancreatic cancer. (2014) (21)
- Genetic Effects and Modifiers of Radiotherapy and Chemotherapy on Survival in Pancreatic Cancer (2011) (21)
- Safety and Efficacy of Everolimus in Adult Patients with Neuroendocrine Tumors (2012) (20)
- Novel oral taxane therapies: recent Phase I results. (2013) (20)
- Pancytopenia and Severe Gastrointestinal Toxicities Associated with 5-Fluorouracil in a Patient with Thymidylate Synthase (TYMS) Polymorphism (2016) (20)
- The First Case of Severe Takotsubo Cardiomyopathy Associated with 5-Fluorouracil in a Patient with Abnormalities of Both Dihydropyrimidine Dehydrogenase (DPYD) and Thymidylate Synthase (TYMS) Genes (2016) (20)
- BRCA-associated pancreatic cancer: the evolving management. (2013) (20)
- Role of platinum agents in the management of advanced pancreatic cancer (2007) (20)
- Secondary tumors of the pancreas: a case series. (2012) (20)
- Elevated Level of Serum Carcinoembryonic Antigen (CEA) and Search for a Malignancy: A Case Report (2016) (20)
- Cardiotoxicity of 5-fluorouracil and capecitabine in a pancreatic cancer patient with a novel mutation in the dihydropyrimidine dehydrogenase gene. (2009) (19)
- Bolus 5-Fluorouracil as an alternative modality to infusion 5-Fluorouracil in a patient with rectal cancer and capecitabine-induced cardiotoxicity. (2009) (19)
- Role of Vitamin D in the Prevention of Pancreatic Cancer (2011) (19)
- Unilateral hand–foot syndrome: an extraordinary side effect of capecitabine (2010) (19)
- Diabetes and pancreatic cancer. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011. (2011) (18)
- Oral Calcium Ameliorating Oxaliplatin-Induced Peripheral Neuropathy. (2004) (18)
- Pancreatic Enzyme Replacement Therapy: A Concise Review. (2019) (18)
- Metastatic Cervical Carcinoma to the Thyroid Gland: A Case Report and Review of the Literature (2006) (18)
- Neurofibromatosis type 1 and GIST: is there a correlation? (2014) (18)
- Identifying and treating fluoropyrimidine-associated hand-and-foot syndrome in white and non-white patients. (2007) (18)
- 5-Fluorouracil dose escalation enabled with PN401 (triacetyluridine): toxicity reduction and increased antitumor activity in mice (2006) (18)
- Mitomycin--C-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: cumulative toxicity of an old drug in a new era. (2011) (18)
- Clinical outcome of pancreatic cancer patients with diabetes mellitus: is diabetes a poor prognostic factor? Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010. (2010) (18)
- New therapeutic directions for advanced pancreatic cancer: cell cycle inhibitors, stromal modifiers and conjugated therapies (2017) (18)
- Pneumonitis related to docetaxel: case report and review of the literature. (2009) (18)
- Pancreatic neuroendocrine tumors: entering a new era. (2012) (18)
- The role of PARP inhibitors in BRCA mutated pancreatic cancer (2021) (18)
- Selecting treatment options in refractory metastatic colorectal cancer (2019) (18)
- KRAS in pancreatic cancer. (2014) (18)
- Pancreatic neuroendocrine tumor with ectopic adrenocorticotropin production: a case report and review of literature. (2013) (17)
- Flavonoids, phenoxodiol, and a novel agent, triphendiol, for the treatment of pancreaticobiliary cancers. (2009) (17)
- Updates of adjuvant therapy in pancreatic cancer: where are we and where are we going? Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010. (2010) (17)
- Successful desensitization with cetuximab after an infusion reaction to panitumumab in patients with metastatic colorectal cancer (2009) (17)
- The clinical significance of autoantibodies in gastrointestinal malignancies: an overview (2007) (17)
- Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (2012) (17)
- Sorafenib-induced acute pancreatitis. (2010) (17)
- Oxaliplatin-mediated autoimmune thrombocytopenia. (2009) (17)
- Capecitabine for the treatment of pancreatic cancer (2019) (17)
- First-Line Treatment of Metastatic Pancreatic Adenocarcinoma: Can We Do Better? (2010) (17)
- Gastrointestinal stromal tumors of the pancreas. (2010) (17)
- Is there a palliative benefit of gemcitabine plus fluoropyrimidines in patients with refractory colorectal cancer? A review of the literature (2009) (16)
- Chronic octreotide therapy can induce pancreatic insufficiency: a common but under-recognized adverse effect (2010) (16)
- Soluble ICAM-1 levels in small-cell lung cancer: prognostic value for survival and predictive significance for response during chemotherapy (2013) (16)
- A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemcitabine-refractory patients with stage IV pancreatic adenocarcinoma and negative tumor hENT1 expression. (2014) (16)
- Advanced stage pancreatic cancer: novel therapeutic options (2014) (16)
- Treatment of metastatic colorectal cancer: from cytotoxic agents to molecular agents and multitargeted strategies. (2006) (16)
- Metastatic pancreatic cancer: the dilemma of quality vs. quantity of life. (2013) (16)
- Managing bevacizumab-related toxicities in patients with colorectal cancer. (2009) (16)
- Oxaliplatin-induced pancreatitis: a case series. (2010) (16)
- MM-398 achieves primary endpoint of overall survival in phase III study in patients with gemcitabine refractory metastatic pancreatic cancer. (2014) (16)
- Recent advances in immunotherapy for pancreatic cancer (2020) (16)
- Gastrointestinal bleeding as initial presentation of melanoma of unknown primary origin: report of a case and review of the literature. (2009) (16)
- Telotristat ethyl: proof of principle and the first oral agent in the management of well-differentiated metastatic neuroendocrine tumor and carcinoid syndrome diarrhea (2017) (16)
- Atypical Hand-and-Foot syndrome in an African American Patient treated with Capecitabine with normal DPD activity: Is there an ethnic disparity? (2008) (16)
- Small intestine bacterial overgrowth: an underdiagnosed cause of diarrhea in patients with pancreatic cancer. (2009) (16)
- Hypersensitivity vasculitis associated with leuprolide (Lupron) (2010) (15)
- Rechallenge with cisplatin in a patient with pancreatic cancer who developed a hypersensitivity reaction to oxaliplatin. Is skin test useful in this setting? (2008) (15)
- Chemotherapy options and outcomes in older adult patients with colorectal cancer. (2009) (15)
- Update on novel therapies for pancreatic neuroendocrine tumors. (2012) (15)
- Expectoration of a lung metastasis in a patient with colorectal carcinoma. (2008) (15)
- Rationale for inhibition of the hedgehog pathway paracrine loop in pancreatic adenocarcinoma. (2011) (15)
- Safety and efficacy of single-day GemOx regimen in patients with pancreatobiliary cancer: a single institution experience (2010) (15)
- Topical henna ameliorated capecitabine-induced hand-foot syndrome (2014) (15)
- Any second-line therapy for advanced pancreatic cancer? Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010. (2010) (14)
- Pharmacokinetics and pharmacodynamics of new drugs for pancreatic cancer (2019) (14)
- TAS-102 an Emerging Oral Fluoropyrimidine. (2016) (14)
- Gemcitabine-induced liver fibrosis in a patient with pancreatic cancer. (2007) (14)
- Cutaneous metastasis in a patient with pancreatic cancer. (2011) (14)
- Is there a role for mitomycin C in metastatic colorectal cancer? (2010) (14)
- Bevacizumab in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for first-line and maintenance treatment of metastatic colorectal cancer (2015) (14)
- Mitomycin-C and capecitabine (MIXE) as salvage treatment in patients with refractory metastatic colorectal cancer: a retrospective study. (2013) (14)
- A phase I study evaluating the effect of CDHP as a component of S-1 on the pharmacokinetics of 5-fluorouracil. (2011) (14)
- Role of anticoagulation in the management of pancreatic cancer. (2009) (14)
- Pancreatic Tuberculosis or Autoimmune Pancreatitis (2014) (14)
- The safety of lanreotide for neuroendocrine tumor (2019) (14)
- A phase I study of MK-5108, an oral aurora A kinase inhibitor, in both monotherapy and in combination with docetaxel in patients with advanced solid tumors. (2010) (13)
- Novel agents in the treatment of unresectable neuroendocrine tumors. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011. (2011) (13)
- Platinum-based therapy in adenosquamous pancreatic cancer: experience at two institutions. (2014) (13)
- Locally advanced pancreatic adenocarcinoma: are we making progress?. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011. (2011) (13)
- Is there a role for herbal medicine in the treatment of pancreatic cancer?. Highlights from the "44th ASCO Annual Meeting". Chicago, IL, USA. May 30 - June 3, 2008. (2008) (13)
- Recent advances in pancreatic cancer: updates and insights from the 2015 annual meeting of the American Society of Clinical Oncology (2016) (13)
- Translational research in pancreatic cancer. Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010. (2010) (13)
- Intraductal papillary mucinous neoplasms of the pancreas: clinical surveillance and malignant progression, multifocality and implications of a field-defect. (2012) (13)
- Early detection of pancreatic cancer. (2012) (13)
- Successful desensitization to oxaliplatin with incorporation of calcium gluconate and magnesium sulfate. (2007) (13)
- Staphylococcus aureus bacteremia related with erlotinib skin toxicity in a patient with pancreatic cancer. (2009) (13)
- Targeting cancers in the gastrointestinal tract: role of capecitabine (2009) (13)
- New Developments in the Treatment of Pancreatic Cancer (2008) (13)
- Second line therapy for advanced pancreatic adenocarcinoma: where are we and where are we going? Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010. (2010) (13)
- Oxaliplatin-induced hyperexcitability syndrome in a patient with pancreatic cancer. (2009) (13)
- A phosphoramidate ProTide (NUC-1031) and acquired and intrinsic resistance to gemcitabine. (2011) (13)
- Novel agents for the treatment of pancreatic adenocarcinoma. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011. (2011) (12)
- Novel agents in the management of pancreatic adenocarcinoma: phase I studies. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011. (2011) (12)
- Retinal neovascularization and hemorrhage associated with the use of imatinib (Gleevec(®)) in a patient being treated for gastrointestinal stromal tumor (GIST). (2012) (12)
- Imatinib-induced hyperbilirubinemia with UGT1A1 (*28) promoter polymorphism: first case series in patients with gastrointestinal stromal tumor (2016) (12)
- The Evolving Field of Stereotactic Body Radiation Therapy in Pancreatic Cancer (2019) (12)
- PARP Inhibitors in Pancreatic Cancer: From Phase I to Plenary Session (2019) (12)
- Amelioration of Symptoms and Reduction of VIP Levels after Hepatic Artery Chemoembolization in a Patient with Sandostatin Resistant VIPoma (2010) (12)
- Phase II trial of DJ-927, an oral tubulin depolymerization inhibitor, in the treatment of metastatic colorectal cancer. (2006) (12)
- Adjuvant Therapy of Pancreatic Cancer: Beyond Gemcitabine (2011) (12)
- Ototoxicity associated with oxaliplatin in a patient with pancreatic cancer. (2013) (12)
- Pulmonary toxicity associated with gemcitabine. (2010) (11)
- A phase I dose-escalation study of edotecarin (J-107088) combined with infusional 5-fluorouracil and leucovorin in patients with advanced/metastatic solid tumors (2010) (11)
- Novel agents in the treatment of pancreatic adenocarcinoma. (2013) (11)
- Management of infusion reactions in clinical trials and beyond: the US and EU perspectives. (2009) (11)
- Erlotinib-induced trichomegaly in a male patient with pancreatic cancer (2010) (11)
- Novel agents and future prospects in the treatment of pancreatic adenocarcinoma. (2013) (11)
- The efficacy of gemcitabine as salvage treatment in patients with refractory advanced colorectal cancer (CRC): a single institution experience. (2011) (11)
- BRCA and pancreatic cancer. (2013) (11)
- Post-transplantation lymphoproliferative disorder with gastrointestinal involvement (2018) (11)
- Flavonoids, phenoxodiol, and a novel agent, triphendiol, for the treatment of pancreaticobiliary cancers (2009) (11)
- Adjuvant therapy of pancreatic cancer: beyond gemcitabine. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011. (2011) (11)
- Pancreatic cancer: are we moving forward yet? Highlights from the Gastrointestinal Cancers Symposium. Orlando, FL, USA. January 20th, 2007. (2007) (11)
- IPdR: a novel oral radiosensitizer (2007) (11)
- Pancreatic neuroendocrine tumors: targeting the molecular basis of disease (2015) (11)
- Breast metastasis of small bowel carcinoid tumor misdiagnosed as primary breast cancer (2009) (11)
- Radiotherapy in the management of pancreatic neuroendocrine tumors (PNET): experience at three institutions. (2013) (11)
- Safety and Efficacy of Combined Yttrium 90 Resin Radioembolization with Aflibercept and FOLFIRI in a Patient with Metastatic Colorectal Cancer (2015) (10)
- Management of Pancreatic Cancer During COVID-19 Pandemic: To Treat or Not to Treat? (2020) (10)
- Capecitabine treatment patterns in patients with gastroesophageal cancer in the United States. (2009) (10)
- Medullary carcinoma of the colon: a case series and review of the literature. (2014) (10)
- Updates in adjuvant therapy in pancreatic cancer: gemcitabine and beyond. Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010. (2010) (10)
- Prognostication of pancreatic adenocarcinoma by expression of thymidine phosphorylase/dihydropyrimidine dehydrogenase ratio and its correlation with survival (2009) (10)
- Combining epidermal growth factor receptor inhibitors and radiation therapy in pancreatic cancer: small step or giant leap? (2009) (10)
- Masitinib in treatment of pancreatic cancer (2018) (10)
- Thromboembolism following removal of femoral venous apheresis catheters in patients with breast cancer. (2004) (10)
- Malignant Ascites Associated with Carcinoma of the Prostate. (2005) (10)
- Locally advanced pancreatic cancer. Looking beyond traditional chemotherapy and radiation. (2013) (10)
- Gastrointestinal stromal tumor of colon: a case report and review of literature. (2014) (10)
- First-line treatment of metastatic pancreatic adenocarcinoma: can we do better? Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010. (2010) (10)
- Management of borderline resectable pancreatic adenocarcinoma. (2012) (10)
- Novel agents in early phase clinical studies on refractory pancreatic cancer. (2012) (10)
- Updates in Pancreatic Neuroendocrine Carcinoma (2010) (10)
- Impact of ethnicity on outcome in pancreatic carcinoma. (2005) (10)
- Update on prognostic and predictive biomarkers for pancreatic neuroendocrine tumors. (2012) (10)
- Is there a benefit from addiction to anti-VEGF therapy in patients with colorectal cancer? (2013) (9)
- The developing trend of monoclonal antibodies in the treatment of colorectal cancer (2007) (9)
- Hepatic failure and hepatorenal syndrome secondary to erlotinib. Safety reminder. (2008) (9)
- Second-line treatment for pancreatic cancer. (2014) (9)
- Diabetes and pancreatic cancer. (2014) (9)
- First-line treatment of metastatic pancreatic cancer. (2012) (9)
- Poorly Differentiated Neuroendocrine Tumor of the Esophagus with Hypertrophic Osteoarthropathy and Brain Metastasis: A Success Story (2016) (9)
- Palliative care from the beginning of treatment for advanced pancreatic cancer. Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010. (2010) (9)
- Lanreotide for the treatment of gastroenteropancreatic neuroendocrine tumors (2016) (9)
- Palmar-plantar erythrodysesthesia in patients receiving capecitabine and intratumor thymidine phosphorylase and dihydropyrimidine dehydrogenase: is there a pharmacologic explanation? (2007) (9)
- Adjuvant treatment of pancreatic cancer in 2009: where are we? Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009. (2009) (9)
- Extraosseous Ewing's Sarcoma of the Pancreas: An Uncommon but Treatable Disease (2017) (9)
- Biomarkers and pharmacogenetics in pancreatic cancer. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011. (2011) (9)
- Does “OPTINAB” strategy (“stop-and-go”) work in treatment of advanced pancreatic cancer (APC) with nab-paclitaxel–gemcitabine? (2017) (9)
- Consequences of the COVID-19 Pandemic on Cancer Clinical Trials. (2021) (9)
- Translational Research in Pancreatic Cancer (2011) (9)
- Erlotinib: the first biologic in the management of pancreatic cancer. (2008) (9)
- Biomarkers in neuroendocrine tumors. (2013) (9)
- Hypokalemia secondary to capecitabine: a hidden toxicity? (2007) (9)
- Colonic metastasis from gastric cancer. (2014) (9)
- BRCA and pancreatic cancer: selection of chemotherapy. (2012) (9)
- Intraductal papillary mucinous neoplasms of the pancreas (IPMNs): epidemiology, diagnosis and future aspects. (2013) (9)
- Management of skin toxicities of anti-EGFR agents in patients with pancreatic cancer and other GI tumors by using electronic communication: effective and convenient. (2010) (8)
- Hepatitis B virus reactivation following imatinib therapy: A comparative review of 9 cases (2018) (8)
- Capecitabine-induced cerebellar toxicity and TYMS pharmacogenetics. (2019) (8)
- What options are available for refractory pancreatic cancer? (2012) (8)
- Treatment of poorly differentiated neuroendocrine carcinoma of the pancreas. (2013) (8)
- Thromboembolism and anticoagulation in pancreatic cancer. (2013) (8)
- Bupropion-Induced Acute Dystonia with Dose Escalation and Use of Naranjo Nomogram (2017) (8)
- Updates on first-line therapy for metastatic pancreatic adenocarcinoma. (2014) (8)
- A phase I/II study of PHY906 plus capecitabine (CAP) in patients (pts) with advanced pancreatic cancer (APC) (2008) (8)
- Phase I study of CNF1010 (lipid formulation of 17-(allylamino)-17-demethoxygeldanamycin: 17-AAG) in patients with advanced solid tumors. (2006) (8)
- Identification of prognostic and predictive markers in pancreatic adenocarcinoma. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011. (2011) (8)
- Scleroderma in a Patient on Capecitabine: Is this a Variant of Hand-Foot Syndrome? (2016) (8)
- Cardiovascular Manifestations of Myeloproliferative Disorders: A Review of the Literature. (1999) (8)
- Expert Review of Clinical Pharmacology (2013) (8)
- Pharmacology and toxicology of the novel investigational agent Cantrixil (TRX-E-002-1) (2016) (8)
- Ampullary and periampullary tumors: translational efforts to meet a challenge in diagnosis and treatment. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011. (2011) (8)
- Current use and potential role of bevacizumab in the treatment of gastrointestinal cancers (2009) (8)
- Severe cutaneous reaction to cetuximab with possible association with the use of over-the-counter skin care products in a patient with oropharyngeal cancer (2009) (8)
- Biomarkers and Pharmacogenetics in Pancreatic Cancer (2011) (8)
- Novel agents in gastroenteropancreatic neuroendocrine tumors. (2013) (8)
- Second line treatment options for pancreatic cancer (2017) (8)
- Pancreatic cancer stem cells: their role in pancreatic cancer patient outcomes and what is future? (2013) (8)
- Palliative care of pancreatic cancer. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011. (2011) (8)
- Incidence and management of ZIv-aflibercept related toxicities in colorectal cancer. (2014) (8)
- Bone Metastasis as the Only Metastatic Site in a Patient with Pancreatic Cancer following Distal Pancreatectomy (2010) (8)
- HIV-associated autoimmune hemolytic anemia complicated by pulmonary embolism following a red blood cell transfusion: case report and review of the literature. (1998) (8)
- Is there a role for liver transplantation in metastatic pancreatic neuroendocrine tumors (PNET)? (2012) (7)
- Intraductal Papillary Mucinous Neoplasia (IPMN) (2010) (7)
- Adjuvant Therapy of Pancreatic Cancer. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011. (2011) (7)
- Phase II study of PHY906 plus capecitabine (CAP) in pts with gemcitabine-refractory pancreatic cancer (PC) and measurement of cytokines. (2010) (7)
- FOLFIRINOX: from the ACCORD study to 2014. (2014) (7)
- Triphendiol (NV-196), development of a novel therapy for pancreatic cancer (2011) (7)
- Heat shock protein inhibitors and vaccines as new agents in cancer treatment (2009) (7)
- Imatinib-induced Ototoxicity in a Patient with Gastrointestinal Stromal Tumor (GIST) (2016) (7)
- Phase II clinical trial of paclitaxel loaded polymeric micelle (GPM) in patients (pts) with advanced pancreatic cancer (APC): Final results (2008) (7)
- Synergistic activity of PHY906 with capecitabine in pancreatic carcinoma (2007) (7)
- Locally advanced pancreatic adenocarcinoma: where are we and where are we going? Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011. (2010) (7)
- Recurrent cutaneous toxic erythema induced by gemcitabine in a patient with pancreatic cancer (2009) (7)
- Chemotherapy and metformin in pancreatic adenocarcinoma and neuroendocrine tumors. (2014) (7)
- Adjuvant therapy for pancreatic cancer. (2014) (7)
- Is there a Role for Herbal Medicine in theTreatment of Pancreatic Cancer (2008) (7)
- Adjuvant Treatment for Ampullary Cancer (2011) (7)
- Stauffer’s Syndrome in Pancreatic Cancer: First Case Report (2017) (7)
- The First-Line Treatment for Advanced Pancreatic Cancer (2010) (7)
- Ampullary and periampullary adenocarcinoma: new challenges in management of recurrence. (2013) (7)
- T cell optimization for the treatment of pancreatic cancer (2017) (7)
- Retrospective Analysis of Capecitabine and Radiation Therapy in the Treatment of Pancreatic Cancer. (2004) (7)
- Neuroendocrine Tumor of the Cystic Duct: A Rare and Incidental Diagnosis (2017) (7)
- Novel therapeutic approaches and mechanisms in neuroendocrine tumors: the role of targeted agents. (2016) (7)
- Multiple lymphomatous polyposis associated with small lymphocytic lymphoma: a unique presentation. (2008) (7)
- A phase II study of capecitabine (CAP) plus PHY906 in patients (pts) with advanced pancreatic cancer (APC). (2016) (7)
- Pancreatic cancer: updates on translational research and future applications. (2013) (7)
- Interaction between capecitabine and gemcitabine with warfarin in a patient with pancreatic cancer. (2008) (7)
- New Drug and Possible New Toxicity - Squamous Cell Carcinoma Following Imatinib in Patients with Gastrointestinal Stromal Tumors. (2016) (7)
- Safety of capecitabine use in patients with liver dysfunction. (2007) (7)
- Erlotinib-induced episcleritis in a patient with pancreatic cancer. (2008) (7)
- Hypersensitivity reactions associated with oxaliplatin and their clinical management (2014) (7)
- Hypersensitivity reactions to oxaliplatin: a retrospective study and the development of a desensitization protocol. (2009) (7)
- Long-term survival on capecitabine in two gemcitabine refractory pancreatic cancer patients. Is there a pharmacogenetic explanation? (2007) (7)
- Translational research in pancreatic cancer. Highlights from the "44th ASCO Annual Meeting". Chicago, IL, USA. May 30 - June 3, 2008. (2008) (7)
- Randomized double-blind phase II trial comparing gemcitabine (GEM) plus LY293111 vs. GEM plus placebo in advanced adenocarcinoma of the pancreas (2005) (7)
- Advancements in the Management of Pancreatic Cancer: 2015 ASCO Gastrointestinal Cancers Symposium (San Francisco, CA, USA. January 15-17, 2015). (2015) (7)
- Phase I study of safety and tolerability of sunitinib in combination with sirolimus in patients with refractory solid malignancies and determination of VEGF (VEGF-A) and soluble VEGF-R2 (sVEGFR2) in plasma (2016) (7)
- Locally advanced pancreatic adenocarcinoma: update and progress. (2012) (7)
- Pancreatic adenocarcinoma with supraclavicular lymph node metastasis: is this the Virchow's node? (2011) (6)
- Drug metabolism and pancreatic cancer (2016) (6)
- Open‐label study to evaluate trifluridine/tipiracil safety, tolerability and pharmacokinetics in patients with advanced solid tumours and hepatic impairment (2019) (6)
- An update on the management of pancreatic neuroendocrine tumors (2018) (6)
- Does OPTIMOX strategy ("stop-and-go" approach) also work in treatment of pancreatic cancer with oxaliplatin-based regimens? (2008) (6)
- Quality of life in patients with pancreatic cancer. (2012) (6)
- Locally advanced pancreatic adenocarcinoma: where are we and where are we going? Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010. (2011) (6)
- Treatment with Lanreotide Depot Following Octreotide Long-Acting Release Among Patients with Gastroenteropancreatic Neuroendocrine Tumors (2018) (6)
- Elderly patients with pancreatic cancer. (2014) (6)
- Pharmacogenetics in pancreatic cancer. Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009. (2009) (6)
- Epidemiology and natural history of central venous access device use and infusion pump function in the NO16966 trial (2014) (6)
- Targeted therapies for pancreatic adenocarcinoma: Where do we stand, how far can we go? (2015) (6)
- Thromboembolism associated with HIV infection: a case report and review of the literature. (2000) (6)
- Is there a role for thiamine in the management of congestive heart failure? (2003) (6)
- CoFactor: Folate Requirement for Optimization of 5-Fluouracil Activity in Anticancer Chemotherapy (2010) (6)
- Tumor markers in pancreatic cancer: 2013. (2013) (6)
- A Phase I/II Open-Label Multicenter Single-Arm Study of FABLOx (Metronomic 5-Fluorouracil Plus nab-Paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin) in Patients with Metastatic Pancreatic Cancer (2019) (6)
- Prolonged survival after splenectomy in Wiskott-Aldrich syndrome: a case report (2011) (6)
- Novel agents for the treatment of pancreatic adenocarcinoma: any light at the end of the tunnel? Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010. (2010) (6)
- Pancreatic Adenocarcinoma Complicated by Sinistral Portal Hypertension (2016) (6)
- Ibrutinib-Induced Vasculitis in a Patient with Metastatic Colon Cancer Treated in Combination with Cetuximab (2020) (6)
- Oral osteonecrosis associated with the use of zoledronic acid: first case of a patient with advanced pancreatic cancer and bone metastases. (2009) (6)
- Is liver resection in metastases of exocrine pancreatic carcinoma justified? (2011) (6)
- First Case of Foot Drop Associated with Capecitabine in a Patient with Thymidylate Synthase Polymorphism (2017) (6)
- Management of a Patient with Metastatic Colorectal Cancer and Liver Metastases (2014) (6)
- New concepts in the treatment strategy of neuroendocrine tumors: the role of biotherapy. (2016) (6)
- Advances in immunotherapy for pancreatic cancer: 2013. (2013) (6)
- Pancreatic cancer: Sorafenib: no effect on efficacy of chemotherapy in pancreatic cancer (2014) (6)
- Pulmonary thromboembolism in AIDS patient with chronic venous insufficiency, pulmonary tuberculosis and breast cancer: a case report and pathophysiology review. (2006) (6)
- Pancreatic Neuroendocrine Tumors: Role of Novel Agents (2011) (6)
- Simplified/Same Day(s)-GOLF as First-line Treatment of Metastatic Carcinoma of Unknown Primary (CUP), Suggestive of Pancreatobiliary Tumors. (2016) (6)
- Phase II trial of DJ-927 as a second-line treatment for colorectal cancer demonstrates objective responses (2005) (6)
- Updates in pancreatic neuroendocrine carcinoma. Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010. (2010) (5)
- Resectable pancreatic cancer: is surgery the best first step? (2012) (5)
- Preclinical research in treatment of pancreatic cancer. (2013) (5)
- EUS-Guided Pancreatic Diagnosis and Beyond (2011) (5)
- Is there a role of radiotherapy in the management of pancreatic neuroendocrine tumors (PNET)? (2012) (5)
- Pancreatic neuroendocrine tumors: role of novel agents. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011. (2011) (5)
- Treatment options in BRAF-mutant metastatic colorectal cancer. (2020) (5)
- Hyperpigmentation due to imatinib: A rare case of cutaneous involvement (2020) (5)
- Research in pancreatic cancer: an update after ASCO 2012. (2012) (5)
- Metastatic gastric large cell neuroendocrine carcinoma: a case report and review of literature. (2012) (5)
- Updates in Locally Advanced Pancreatic Cancer (2010) (5)
- Squamous cell carcinoma of the pancreas. (2014) (5)
- The first-line treatment for advanced pancreatic cancer. Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010. (2010) (5)
- Plasmablastic Lymphoma Mimicking Acute Pancreatitis (2016) (5)
- Aggressive Burkitt-Like Lymphoma of Colon in a Patient With Prior Celiac Disease (2006) (5)
- Erlotinib: the first biologic in the management of pancreatic cancer (2008) (5)
- Rectal Dieulafoy's lesion: a comprehensive review of patient characteristics, presentation patterns, diagnosis, management, and clinical outcomes. (2020) (5)
- Radiation recall gastritis secondary to erlotinib in a patient with pancreatic cancer. (2014) (5)
- Regorafenib: from bench to bedside in colorectal cancer (2013) (5)
- Phase III multicenter randomized clinical trial to evaluate the safety and efficacy of CoFactor/5-fluorouracil/bevacizumab versus leucovorin/5-fluorouracil/bevacizumab as initial treatment for metastatic colorectal carcinoma. (2006) (5)
- Three-drug combination regimen in pancreatic cancer treatment: are we there yet? (2011) (5)
- Adjuvant therapy of pancreatic cancer. (2012) (5)
- Atypical toxicity associated with 5-Fluororacil in a DPD-deficient patient with pancreatic cancer. Is ethnicity a risk factor? (2008) (5)
- Pharmacogenomics update in pancreatic cancer. (2014) (5)
- Evidence for increased incidence of dihydropyrimidine dehydrogenase (DPD) deficiency in African Americans compared to Caucasians (2005) (5)
- Phase I/II study of capecitabine and PHY906 in hepatocellular carcinoma (2008) (5)
- First line therapy for metastatic pancreatic cancer. (2013) (5)
- Cerebrovascular Accidents Associated with Sorafenib in Hepatocellular Carcinoma (2011) (5)
- Anaphylactic reaction associated with intravenous administration of folinic acid in a patient with colon cancer. (2011) (5)
- Safety and efficacy of radiofrequency ablation with aflibercept and FOLFIRI in a patient with metastatic colorectal cancer. (2014) (5)
- A phase I study of PHY906 as a modulator of irinotecan (CPT-11) in patients with advanced solid tumors. (2010) (5)
- Maintenance therapy with capecitabine in patients with locally advanced unresectable pancreatic adenocarcinoma (2014) (5)
- Rheumatoid arthritis associated with the use of Sandostatin® LAR® depot in a patient with pancreatic neuroendocrine tumor. An association or a coincidence? The first case report. (2011) (4)
- Updates on treatment of gemcitabine-refractory pancreatic adenocarcinoma. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011. (2011) (4)
- Management of Bisphosphonate-Related Osteonecrosis of the Jaw (2009) (4)
- Genetic factors affecting patient responses to pancreatic cancer treatment (2016) (4)
- Long term survival on S-1 monotherapy in a patient with recurrent stage IV pancreatic cancer. (2008) (4)
- Translational research. New findings and potential future applications in pancreatic adenocarcinoma. (2012) (4)
- Pancreatic cancer: what about screening and detection? (2013) (4)
- Mitomycin-induced interstitial pneumonitis in a patient with BRCA2 associated metastatic pancreatic carcinoma. (2010) (4)
- Pancreatic Cancer: Are We Moving Forward Yet? (2007) (4)
- Association of RETN C-420G single nucleotide polymorphism with type 2 diabetes mellitus in Pakistani Punjabi Rajput population. (2018) (4)
- Congestive heart failure secondary to gemcitabine nab-paclitaxel in patients with pancreatic cancer. (2014) (4)
- Attenuated regimen of biweekly gemcitabine/nab-paclitaxel in patients aged 65 years or older with advanced pancreatic cancer (2020) (4)
- Novel treatment approaches for locally advanced pancreatic cancer. (2014) (4)
- Rash associated with the use of pegylated filgrastim in a patient with advanced pancreatic cancer (2009) (4)
- Risk determination for pancreatic cancer. (2014) (4)
- New therapeutic strategies in the second line setting of advanced or metastatic pancreatic adenocarcinoma. (2013) (4)
- Gastrointestinal bleeding associated with concurrent capecitabine and radiotherapy in patients with pancreatic cancer. (2005) (4)
- Medical record review of transition to lanreotide following octreotide for neuroendocrine tumors. (2019) (4)
- Gastroenteropancreatic neuroendocrine tumors: hormonal treatment updates. (2014) (4)
- Controlling Chemotherapy-Related Side Effects with Chinese Medicine (2010) (4)
- Novel agents and new combination treatments on phase I studies on solid tumors and pancreatic cancer. (2012) (4)
- Pancreatic neuroendocrine tumors: does chemotherapy work? (2014) (4)
- A 25 year old woman presenting with bleeding disorder and nystagmus (2001) (4)
- Perforation of the Colon During Imatinib Mesylate (Gleevec) Treatment in a Patient with Chronic Myeloid Leukemia (CML) (2016) (4)
- Is there a role for second line therapy in advanced pancreatic cancer? (2014) (4)
- 2016 Gastrointestinal Cancers Symposium: update on pancreatic cancer (2016) (4)
- A phase I study evaluating the effect of CDHP as a component of S-1 on the pharmacokinetics (PK) of 5-fluorouracil (5-FU) (2008) (4)
- A phase I, open-label study evaluating the safety and pharmacokinetics of trifluridine/tipiracil in patients with advanced solid tumors and varying degrees of renal impairment (2021) (4)
- New developments in the management of borderline resectable pancreatic cancer. (2013) (4)
- Screening and detection of pancreatic cancer. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011. (2011) (4)
- Clinical studies in the second line setting of advanced pancreatic cancer: are we making any progress? (2012) (4)
- Lessons Learnt from COVID-19: How Can We Prepare for Another Pandemic? (2020) (4)
- PET scanning: worth the cost in cancer? Not for all cancers--it's not reliable enough yet. (2014) (4)
- Options for the treatment of gemcitabine-resistant advanced pancreatic cancer: are we there yet? (2010) (4)
- Updates in locally advanced pancreatic cancer. Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010. (2010) (4)
- Intraductal papillary mucinous neoplasms of the pancreas (IPMNs): new insights on clinical outcomes and malignant progression. (2014) (4)
- Gemcitabine as salvage treatment in patients with poorly differentiated pancreatic neuroendocrine tumors: a case series. (2014) (4)
- Alternative Treatment Options in Patients with Colorectal Cancer Who Encounter Fluoropyrimidine-Induced Cardiotoxicity (2020) (4)
- Management of advanced pancreatic cancer (2009) (4)
- The role of biliary drainage in patients with pancreatic adenocarcinoma. (2014) (4)
- Highlights on the first line treatment of metastatic pancreatic cancer. (2012) (4)
- Platelet count less than SHARP: what does a case series reveal? (2010) (4)
- A phase I study of bi-weekly administration of 24-h gemcitabine followed by 24-h irinotecan in patients with solid tumors (2007) (4)
- Primary squamous cell carcinoma of the liver. (2009) (4)
- Interaction between Gemcitabine and Warfarin Causing Gastrointestinal Bleeding in a Patient with Pancreatic Cancer. (2005) (3)
- Burden of Proof: Evaluating the Efficacy of Tumor Mutational Burden (TMB) in Predicting Response to Immune Checkpoint Inhibitors. (2020) (3)
- Treatment for refractory pancreatic cancer. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011. (2011) (3)
- Safety and Efficacy of s-MOX Regimen in Patients with Colorectal Cancer Who Developed Cardiotoxicity Following Fluoropyrimidine Administration: A Case Series (2020) (3)
- Diabetes and pancreatic cancer. (2014) (3)
- Association of Pharmacogenetics With Adverse Events of Fluorouracil/Capecitabine in Patients With Cancer. (2021) (3)
- Pharmacogenetics in neuroendocrine tumors of the pancreas. (2014) (3)
- Novel agents for the treatment of pancreatic cancer. (2014) (3)
- A case of Down syndrome who developed pancreatic cancer: a case report and review of literature. (2010) (3)
- Neuroendocrine tumors: treatment updates. (2013) (3)
- Pharmacogenetics in pancreatic cancer. (2014) (3)
- Capecitabine as salvage therapy for a pancreatic cancer patient with extensive liver metastases and associated impairment of liver function. (2008) (3)
- Phase 1 trials in pancreatic cancer. (2014) (3)
- Fluoropyrimidines as Radiation Sensitizers (2003) (3)
- Pulmonary Tuberculosis Versus Recurrent Chemotherapy-Induced Pneumonitis: A Clinical Dilemma (2017) (3)
- Epistaxis secondary to panitumumab in a patient with colon cancer. (2012) (3)
- Adjuvant treatment for ampullary cancer. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011. (2011) (3)
- Does erlotinib restore chemosensitivity to chemotherapy in pancreatic cancer? A case series. (2011) (3)
- Pancreatic cancer in 2014. (2014) (3)
- Colon Mass as a Secondary Metastasis from Cholangiocarcinoma: A Diagnostic and Therapeutic Dilemma (2016) (3)
- Lower 24-Month Relative Survival among Black Patients with Non- Hodgkin’s Lymphoma: An Analysis of the SEER Data 1997–2015 (2021) (3)
- Hepatic failure and hepatorenal syndrome secondary to erlotinib: a possible etiology of complications in a patient with pancreatic cancer. (2010) (3)
- Castleman disease in an HIV-infected patient with Kaposi sarcoma. (2001) (3)
- Pharmacogenetic Variants in the DPYD and TYMS Genes are Clinically Significant Predictors of Fluoropyrimidine Toxicity: Are We Ready for Use in our Clinical Practice (2020) (3)
- Should ageism be a stratification factor in patients with pancreatic cancer? (2014) (3)
- Novel drug targets based on association between inflammation and pancreatic ductal adenocarcinoma. (2010) (3)
- Trends in Incidence and Outcomes of Clostridium difficile Colitis in Hospitalized Patients of Febrile Neutropenia (2019) (3)
- Intraductal papillary mucinous neoplasia (IPMN). Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010. (2010) (3)
- Screening and Detection of Pancreatic Cancer (2011) (3)
- New tools and novel approaches in treating locally advanced pancreatic adenocarcinoma. (2012) (3)
- A Rare Occurrence of Isolated Brain Metastases from Gastric Cancer (2019) (3)
- Chin tremors associated with paroxetine in a patient with pancreatic adenocarcinoma. (2013) (3)
- Second-line therapy in pancreatic cancer. (2013) (3)
- First line treatment for metastatic pancreatic adenocarcinoma: looking for the step forward. (2014) (3)
- Hepatectomy for Breast Cancer Metastasis and Sarcoma are more likely to have Adverse Outcomes than Hepatectomy for Primary Hepatocellular Cancer or for Colorectal Metastasis. (2020) (3)
- Use of supportive care for symptom management in pancreatic cancer: application of clinical research to patient care. (2012) (3)
- Role of methylphenidate in the treatment of fatigue in advanced pancreatic cancer population (2016) (3)
- Immunohistochemical expression of p53, p63, c-myc, p21(WAF1/cip1) and p27(kip1) proteins in urothelial bladder carcinoma: correlation with clinicopathological parameters. (2014) (3)
- Cytotoxic Chemotherapy for Metastatic Colorectal Cancer (2007) (3)
- Translational research in pancreatic adenocarcinoma. (2014) (3)
- Nanoliposomal irinotecan for treating pancreatic cancer (2016) (3)
- Comparison of efficacy and safety of capecitabine (CAP) compared with intravenous continuous infusion (CIV) of 5-FU administration in advanced colorectal cancer (CRC) (2005) (3)
- Novel modalities in the treatment of patients with KRAS-mutated colorectal cancer (2011) (3)
- Prognostic factors in pancreatic cancer. (2013) (2)
- Updates on the use of neoadjuvant therapy in borderline resectable pancreatic cancer. (2014) (2)
- Prospective Evaluation of Effect of Metformin on Activation of AMP-activated Protein Kinase (AMPK) and Disease Control in a Sub-group Analysis of Patients with GI Malignancies (2020) (2)
- Association between Rash and a Positive Drug Response Associated with Vinorelbine in a Patient with Primary Peritoneal Carcinoma (2013) (2)
- Therapeutic Challenges in Neuroendocrine Tumors. (2017) (2)
- Phase I/II study of PHY906/capecitabine in hepatocellular carcinoma (2007) (2)
- Radioembolization in the treatment of neuroendocrine tumors of the pancreas. (2014) (2)
- Bone lesions in recurrent glucagonoma: A case report and review of literature. (2012) (2)
- Antiangiogenesis therapy in second line metastatic colorectal cancer: similar but different (2013) (2)
- Cutaneous Metastasis of Gastroenteropancreatic Neuroendocrine Tumors (GEP-Nets). (2018) (2)
- Small cell carcinoma of the colon arising in a carcinoid tumor. (2013) (2)
- Second cancer risk in hairy cell leukemia. (2001) (2)
- Potential Impact of Delay in Cancer Screening due to COVID-19. (2020) (2)
- An update on surgical staging of patients with pancreatic cancer. (2012) (2)
- Targeted agents in treatment of neuroendocrine tumors of pancreas. (2014) (2)
- Uridine triacetate - an antidote in the treatment of 5-fluorouracil or capecitabine poisoning (2019) (2)
- Epidemiology and natural history of central venous access device (CVAD) use and infusion pump performance among patients (pts) treated for metastatic colorectal cancer (mCRC): Analysis from the NO16966 trial. (2011) (2)
- COVID-19 Disease and SARS-CoV-2 Vaccination in Patients with Cancer (2021) (2)
- Up-regulation of thymidine phosphorylase (TP) by radiotherapy (RT): a phase I study of capecitabine (CAP) with concurrent RT for pts with locally advanced (LA) pancreatic cancer (Pan Ca) (2004) (2)
- Allergic contact dermatitis associated with Biosyn suture in a patient with gastroesophageal junction cancer (2013) (2)
- Primary peritoneal carcinoma in complete remission: a case report. (2011) (2)
- Biomarkers in pancreatic adenocarcinoma. (2014) (2)
- First Case of the Cervical Lymph Node as the Only Site of Metastasis from Anal Cancer (2017) (2)
- Pharmacogenomics in pancreatic adenocarcinoma: new data and their clinical implications. (2013) (2)
- Phase II study of mFOLFOX6 with bevacizumab (Bev) in metastatic gastric and esophageal (GE) adenocarcinoma. (2010) (2)
- Nutritional status of patients with locally advanced pancreatic cancer. (2010) (2)
- Pancreatic Cancer and Personalized Medicine: Can Genomics Facilitate Early Diagnosis or Improve Therapeutic Outcomes? (2010) (2)
- An unusual case of “jaundice” (2009) (2)
- Evidence-based Anticancer Materia Medica for Pancreatic Cancer (2012) (2)
- New Potential Options for SBRT in Pancreatic Cancer. (2021) (2)
- A phase I study of sunitinib in combination with sirolimus in adults with advanced refractory malignancies. (2009) (2)
- Pancreatic cancer: translating lessons from mouse models. (2009) (2)
- Updates on first-line treatment of metastatic pancreatic adenocarcinoma. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011. (2011) (2)
- Early Detection and Screening of Pancreatic Cancer (2011) (2)
- Biological identification of ampullary adenocarcinomas. (2014) (2)
- Pancreatic metastasis from colon carcinoma treated with radiotherapy with palliative benefit. (2010) (2)
- Pulmonary Blastoma with Submandibular, Scrotum and Adrenal Metastases: Case Report (2011) (2)
- Hand-foot syndrome (HFS) in patients treated with capecitabine (CAP) and the role of thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD). (2006) (2)
- Up-regulation of thymidine phosphorylase (TP) by radiotherapy (RT): a phase I study of capecitabine (CAP) with concurrent RT for pts with locally advanced (LA) pancreatic cancer (Pan Ca). (2004) (2)
- EUS-guided pancreatic diagnosis and beyond. Highlights from the "2011 ASCO gastrointestinal cancers symposium". San Francisco, CA, USA. January 20-22, 2011. (2011) (2)
- How Shall We Name the Chemotherapy Administration Before and After Metastasectomy? How About “M-Neoadjuvant” and “M-Adjuvant”? (2010) (2)
- Palliative Care of Pancreatic Cancer (2011) (2)
- Prognostic and predictive biomarkers in gastroenteropancreatic neuroendocrine tumors. (2013) (2)
- A phase I study of DX 8951f (exatecan mesylate for injection) in patients with renal dysfunction. (2004) (2)
- Early detection and screening of pancreatic cancer. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011. (2011) (1)
- Abdominal presentation of Burkitt's lymphoma in an HIV-positive patient. (1998) (1)
- Pineal germinoma followed by hematogenous metastases. (2003) (1)
- Is there an Ethnic Predisposition to Developing Brain Metastases (BM) in Asian Patients with Colorectal Cancer? (2020) (1)
- Gemcitabine-induced hepatitis in a pancreatic cancer patient receiving adjuvant therapy following metastasectomy. (2009) (1)
- Adenocarcinoma ex goblet cell carcinoid in a renal transplant patient: a case report and review of the literature. (2013) (1)
- Translational research in pancreatic cancer. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011. (2011) (1)
- Is S-1 a potential game changer in adjuvant therapy of pancreatic cancer? (2013) (1)
- Life threatening pulmonary embolus in a factor V Leiden carrier on oral contraceptives: a case report. (1997) (1)
- Revising you the staging for pancreatic cancer in 2012. (2012) (1)
- Biomarkers in pancreatic neuroendocrine tumors. (2014) (1)
- Upregulation of thymidine phosphorylase (TP) by radiation (XRT): Phase II study of capecitabine (CAP) with XRT in pts with locally advanced (LA) pancreatic cancer. (2006) (1)
- Highlights on novel imaging methods of pancreatic cancer. (2013) (1)
- COVID-19 Clinical Research (2020) (1)
- Urgent Calls for Effective Earlier Disease Detection and Multi-Modal Therapeutic Strategies in Pancreatic Cancer (2009) (1)
- Therapeutic tools in pancreatic cancer. (2009) (1)
- Therapy-Associated Myeloid Dysplasia in a Long-Surviving Patient with Pancreatic Cancer (2016) (1)
- Review of Oncology and Transplant Literature for the Management of Hepatic and Pancreatic Resections in Jehovah's Witnesses. (2021) (1)
- Treatment for Refractory Pancreatic Cancer (2011) (1)
- The role of cancer stem cells and the therapeutic potential of TRX-E-002-1 in ovarian cancer (2018) (1)
- Three Weeks of a Four Week Course or Twice Weekly for Four Weeks of a Four Week Course to Patients with Advanced Solid Tumors (2013) (1)
- Positron emission tomography imaging of pancreatic cancer. (2014) (1)
- Dihydropyrimidine dehydrogenase deficiency (DPD) in GI malignancies: Experience of 4 years. (2006) (1)
- Outstanding Outcome of Pancreatic Cancer: What Lessons Do We Learn (2020) (1)
- New developments in the management of borderline resectable pancreatic cancers. (2013) (1)
- First Analysis of Same-day Pegfilgrastim Use with Concurrent Capecitabine-based Regimens in Patients with Gastrointestinal Malignancies. (2021) (1)
- Updates in management of ampullary carcinomas. (2014) (1)
- Phase 1 experience with BIIB021, an oral, synthetic, non-ansamycin Hsp90 inhibitor (2007) (1)
- Pancreatic cancer: new hopes for early detection and a future screening tool? (2014) (1)
- Dihydropyrimidine dehydrogenase gene (DPYD) polymorphism among Caucasian patients (pts) with 5-FU and capecitabine (CAP)-related toxicity. (2009) (1)
- The First Study Evaluating the Safety of Pre-Surgery Administration of Metformin in Patients with Colorectal and other Gastrointestinal Cancers and Effect on Cancer Stem Cells. (2021) (1)
- Does Neoadjuvant Therapy Improve Outcome in Resectable PC? Gastrointestinal Cancers Symposium 2019. (2019) (1)
- New Developments in the Treatment of Locally Advanced Pancreatic Cancer (2009) (1)
- New Developments in the Treatment of Pancreatic Cancer: Highlights from the 44th ASCO Annual Virtual Meeting, May 29-31, 2020. (2020) (1)
- Survival Benefits and Disparities in Adjuvant Radiation Therapy for Patients with Pancreatic Cancer. (2021) (1)
- Is There a Role of Targeted Agents in the Management of Adrenocortical Cancers? (2012) (1)
- Is There any Survival Benefit of Maintenance Chemotherapy Following Adjuvant Chemotherapy in Patients with Resected Pancreatic Cancer Patients with Post-Surgery Elevated CA 19-9? (2020) (1)
- Novel agents in gastroenteropancreatic neuroendocrine tumors: Highlights from the "2013 ASCO gastrointestinal cancers symposium". San Francisco, CA, USA. january 24-26, 2013 (2013) (1)
- Thromboembolism and pancreatic cancer. (2014) (1)
- A novel schedule of erlotinib/capecitabine (7/7) as salvage therapy in previously treated advanced pancreatic adenocarcinoma: a case series (2016) (1)
- Clinical and laboratory biomarkers in the management of pancreatic adenocarcinoma. (2012) (1)
- Pancreatic neoplasm in 2012: an update. Tissue is an issue! (2012) (1)
- Prognostication of pancreatic adenocarcinoma by expression of thymidine phosphorylase (TP) and its correlation with survival (2007) (1)
- Sweeping KRAS generalizations: are we depriving patients of an effective treatment? A novel KRAS mutation and dramatic response to panitumumab in a patient with metastatic colorectal cancer (2011) (1)
- Management of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in 2017. (2017) (1)
- Gastrointestinal Stromal Tumors Incidentalomas: A Case Series. (2020) (1)
- First case report associating gemcitabine with hypersensitivity reaction in a patient with pancreatic cancer. (2010) (1)
- Retrospective Analysis of Patients with Gynecological Uterine Sarcomas: Leiomyosarcomas and other Histological Subtypes at a Single Institution from 1996 to 2015. (2020) (1)
- TREATMENT OF LOCALLYADVANCED PANCREATIC CANCER: THE ROLE OF RADIATION THERAPY (2012) (1)
- Effect of PHY906 on capecitabine (CAP)-induced diarrhea in patients with GI malignancies. (2009) (1)
- Delicate Balance Between Quality and Quantity of Life: Palliative Chemotherapy for Metastatic Pancreatic Adenocarcinoma. (2020) (1)
- Evidence-based Anticancer Materia Medica for Colorectal Cancer (2012) (0)
- Diabetes and Pancreatic Cancer-2014 (2014) (0)
- Utilizing endoscopic ultrasound-guided fine needle aspiration in identifying molecular targets for pancreatic cancer. (2013) (0)
- Retrospective analysis of coagulation abnormalities in patients receiving capecitabine (CAP) and warfarin (WAR) (2005) (0)
- Locally advanced pancreatic cancer. (2013) (0)
- Acquired factor VII deficiency following FOLFOX in a patient with colorectal cancer who was also DPD deficient (2016) (0)
- Syncope Secondary to Mastocytosis. (2000) (0)
- Palpable lesions resistant to corticosteroids. (1999) (0)
- Successful re-challenge with panitumumab (PAN) in patients (pts) with GI cancers who developed hypersensitivity reactions (HSR) to cetuximab (CET) (2008) (0)
- Organoid Personalized Therapeutics and the Pancreatic Adenocarcinoma Signature Stratification for treatment (PASS) – 01 trial (2020) (0)
- Varicella Zoster Meningitis Preceeded by Thrombophlebitis in a Patient with Hodgkin's Disease (2000) (0)
- New developments in the treatment of locally advanced pancreatic cancer. Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009. (2009) (0)
- Challenges to Treat Cancer Patients During COVID-19 Pandemic. (2020) (0)
- Chemoradiation in the Management of Pancreatic Neuroendocrine Tumors (PNET) (2012) (0)
- A pharmacokinetic (PK) dose escalation study of DX-8951f (DX) in adult cancer patients with hepatic dysfunction: A comparison of the NCI hepatic dysfunction criteria and the Child-Pugh classification. (2004) (0)
- Screening of Pancreatic Cancer. (2018) (0)
- Epidemiology and natural history of central venous access device use and infusion pump function in the NO 16966 trial (2014) (0)
- An AIDS patient with hallucinations and pyrexia. (1999) (0)
- Mental Disorder and Neutropenia. (2002) (0)
- Diagnosis and Treatment of Kaposi's Sarcoma. (2001) (0)
- Imatinib Induced Hypopigmentation and Neutropenia in a Patient with Gastric Gastrointestinal Stromal Tumor (2022) (0)
- Early Resected Pancreatic Head Adenocarcinoma with Development of Sole Osteoblastic/Osteolytic Metastatic Disease: A Case Report and Review of the Literature (2021) (0)
- Is there a palliative benefit of gemcitabine (G) plus fluoropyrimidines (F) in patients (pts) with refractory colorectal cancer (CRC) (2008) (0)
- Increasing access to multidisciplinary care in pancreatic cancer (2020) (0)
- Cancer on Twitter. (2020) (0)
- Abstract 4668: Genetic effects and modifiers of radiotherapy and chemotherapy on survival in pancreatic cancer (2011) (0)
- Amyloid Deposition and Infiltrative Cardiomyopathy (2005) (0)
- From Screening to Treatment of Pancreatic Cancer: A Comprehensive Review. (2021) (0)
- Anaphylactic Reaction To Intravenous Administration Of Folinic Acid: A Case Report (2012) (0)
- UAB's experience with concurrent capecitabine (CAP) and radiotherapy (RT) in Pts with resected (RES) or locally advanced (LA) pancreatic cancer (Pan Ca). (2004) (0)
- Years of Fight against Pancreatic Cancer by RGB: Lessons to be Learnt. (2020) (0)
- First Case Report of Metastatic Squamous Cell Carcinoma of Lung Associated with Mounier-Kuhn Syndrome and Review of Literature (2017) (0)
- Adjuvant strategies for resectable pancreatic cancer: have we made progress? (2012) (0)
- The use of real-time online updates for physicians. (2009) (0)
- Does Hospital Type Affect Lymph Node Evaluation in Intrahepatic Cholangiocarcinoma? Analysis of the National Cancer Database (2022) (0)
- Safety and efficacy of single-day GemOx (S-GemOx) regimen in pts with pancreatobiliary cancer (PBC). (2009) (0)
- Giant cell arteritis. (1997) (0)
- Screening of Colorectal Cancer (2010) (0)
- A pharmacokinetic (PK) dose escalation study of DX-8951f (DX) in adult cancer patients with hepatic dysfunction: A comparison of the NCI hepatic dysfunction criteria and the Child-Pugh classification (2004) (0)
- Social Distancing and the Power of Touch. (2020) (0)
- Cardiac Complications of Myeloproliferative Disorders. (2001) (0)
- Adjuvant trials for pancreatic cancer: where are we going and what is needed? (2011) (0)
- S1673 Acute Pancreatitis Secondary to Pembrolizumab-Induced Hypertriglyceridemia: First Clinical Experience (2022) (0)
- Novel anti-angiogenic agents for colorectal cancer. Are we moving on? (2012) (0)
- First Case of Topical 5-FU Therapy for Cutaneous Metastasis in a Patient with Colon Cancer (2020) (0)
- Safety and Efficacy of Capecitabine as a Radiosensitizer in Adjuvant Chemoradiation Therapy for Pancreatic Adenocarcinoma (2014) (0)
- Prognostic and predictive biomarkers in gastroenteropancreatic neuroendocrine tumors: Highlights from the "2013 ASCO gastrointestinal cancers symposium". San Francisco, CA, USA. january 24-26, 2013 (2013) (0)
- Advances in Pancreatic Cancer Treatment (2007) (0)
- Front & Back Matter (2012) (0)
- Corrigendum to Hyperpigmentation due to imatinib: A rare case of cutaneous involvement (2020) (0)
- Updates on Pancreatic Cancer - Highlights from the “48th Annual Pancreas Club Meeting”. Chicago, IL, USA. May 2-3, 2014 (2014) (0)
- Clinicopathological features of lupus anticoagulant; experience at AFIP during last seven years. (2005) (0)
- Pancreatoblastoma. (2020) (0)
- Cisplatin can be Safely Administered After Hypersensitivity to Carboplatin (2011) (0)
- Is There a Genetic Component Responsible for Hypercoagulation in Pancreatic Cancer Patients ? (2009) (0)
- Pancytopenia after administration of hyperthermic intraperitoneal chemotherapy with mitomycin-C: local therapy and systemic toxicity (2021) (0)
- Pancrelipase-Induced Hypersensitivity Reaction: Case Report and Review of Literature. (2018) (0)
- Abstract #5101: Pre-clinical toxicology of triphendiol (2009) (0)
- Small Bowel Neuroendocrine Tumors with Inguinal Metastases: A Diagnostic and Therapeutic Dilemma (2016) (0)
- Headache Agitation or Anxiety Anorexia Seizures Transient insomnia Asthenia Confusion Ataxia Dry mouth Flushing Delusions Taste disorders Hypertension , tachycardia , chest pain Depersonalization Tremor Tinnitus Hallucinations Rash Alopecia (2017) (0)
- UAB's experience with concurrent capecitabine (CAP) and radiotherapy (RT) in Pts with resected (RES) or locally advanced (LA) pancreatic cancer (Pan Ca) (2004) (0)
- Pancreatic cancer and thromboembolism in the ambulatory community. (2012) (0)
- Neuroendocrine Tumors : Treatment Updates Highlights from the “ 2013 ASCO Annual Meeting ” . Chicago , IL , USA ; May 30-June 4 , 2013 (2013) (0)
- Biomarkers in Pancreatic Adenocarcinoma Highlights from the “ ASCO Annual Meeting ” . Chicago , IL , USA . May 30-June 3 , 2014 (2014) (0)
- Pharmacogenetics of Colorectal Cancer and Individualized Management (2010) (0)
- A phase I study of bi-weekly administration of 24-hr gemcitabine (GEM) followed by 24-hr irinotecan (CPT-11) in patients with solid tumors (2005) (0)
- Update on novel therapies for pancreatic neuroendocrine tumors: 2013. (2013) (0)
- Adjuvant treatment for pancreatic cancer. (2014) (0)
- Positron Emission Tomography Imaging of Pancreatic Cancer Highlights from the “ 2014 ASCO Gastrointestinal Cancers Symposium ” (2014) (0)
- Developments in the Management of Advanced Non Small Cell Lung Cancer (2013) (0)
- The management of gastroenteropancreatic neuroendocrine tumors with somatostatin analogues. (2014) (0)
- A Comprehensive Review of Management of Colorectal Liver Mets in the Current Era. (2022) (0)
- Clinical Diagnosis DYSPHAGIA SECONDARY TO A SOLITARY PLASMACYTOMA (2012) (0)
- Neoadjuvant Therapy (NAT) in Localized Pancreatic Cancer: Should We Do It and What Should We Do? (2021) (0)
- Role of neoadjuvant therapy in management of pancreatic cancer. (2014) (0)
- Bee Sting and Urticaria. (2001) (0)
- Preclinical Research in Treatment of Pancreatic Cancer Highlights from the “ 2013 ASCO Annual Meeting ” . Chicago , IL , USA ; May 30-June 4 , 2013 (2013) (0)
- Advanced stage pancreatic cancer: novel therapeutic (2014) (0)
- Hematological Complications of Acute Pancreatitis: A Review. (2001) (0)
- A Rare Case of Gemcitabine-Induced Pulmonary Hypertension (2019) (0)
- Racial Differences in Accepting Pegfilgrastim Onpro Kit (On-Body Injector) Use Among Cancer Patients. (2019) (0)
- Variant hypersensitivity reaction (HSR) presented with persistent dry cough after receiving oxaliplatin in a pancreatic cancer patient. (2009) (0)
- Ethnic Differences in Hematologic Toxicity from Imatinib in Patients with Gastrointestinal Stromal Cell Tumor (GIST): Coincidence or a Real Phenomenon (2019) (0)
- Esophageal Cancer: Chemotherapy and Targeted Agents for Stage IV Cancer (2010) (0)
- Metastatic Primary Neuroendocrine Carcinoma of the Breast: A Case Report Describing Successful Treatment using Letrozole and Abemaciclib Combination Therapy (2022) (0)
- Prognosticationofpancreatic adenocarcinomabyexpression ofthymidinephosphorylase/ dihydropyrimidine dehydrogenaseratioandits correlationwithsurvival (2009) (0)
- Elevated Level of Serum Carcinoembryogenic Antigen (CEA) and Search for a Malignancy: A Case Report: 1338 (2016) (0)
- Macroglossia in a Patient With Recurrent Multiple Myeloma. (2000) (0)
- Eruptive Xanthomas in a 32-Year-Old Man (2005) (0)
- Sunitinib as Successful Maintenance Therapy for Recurrent Pancreatic Serous Cystadenocarcinoma. (2020) (0)
- Henoch-Schönlein Purpura Presenting as a Rash and Proteinuria in a 59-Year-Old Woman. (1999) (0)
- Hypokalemia among patients receiving capecitabine (CAP) for GI malignancies (2005) (0)
- Successful desensitization with cetuximab (CET) after hypersensitivity reaction (HSR) to panitumumab (PAN) and CET in patients (pts) with metastatic colorectal cancer (mCRC) (2008) (0)
- Pharmacogenetics and other molecular targets in the management of pancreatic adenocarcinoma. Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010. (2010) (0)
- Updates on Pancreatic Cancer (2014) (0)
- Sjogren's syndrome and Lymphoma. (1998) (0)
- Myelodysplastic Syndrome in Patients with Gastro-Pancreatic Malignancies: A Case Series and Review of Literature. (2020) (0)
- Von Willebrand Disease and Pregnancy. (2001) (0)
- Anal Squamous Cell Carcinoma in a Patient with Myasthenia Gravis: Is Immunosuppression the Main Underlying Etiology? (2017) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Muhammad Wasif Saif?
Muhammad Wasif Saif is affiliated with the following schools:
